SCHEMBL3307591

SCHEMBL3307591

COC(=O)[C@H](CC(=O)N1CCC(N2Cc3ccccc3NC2=O)CC1)Cc1cc(Cl)c(N)c(C(F)(F)F)c1

nearest known ligand 0.69

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
CALCRL Q16602 19/20 0.69
RAMP1 O60894 2/20 0.69
CALCA P06881 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3307593 1.00 CALCRL (0.69) CALCRLRAMP1CALCA
SCHEMBL4507227 0.92 CALCRL (0.61) CALCRLRAMP1CALCA
SCHEMBL4507225 0.92 CALCRL (0.61) CALCRLRAMP1CALCA
SCHEMBL3307004 0.91 CALCRL (0.70) CALCRLRAMP1
SCHEMBL3309876 0.91 CALCRL (0.70) CALCRLRAMP1
SCHEMBL3307158 0.91 CALCRL (0.56) CALCRLRAMP1
SCHEMBL3316489 0.90 CALCRL (0.57) CALCRLRAMP1
SCHEMBL3316492 0.90 CALCRL (0.57) CALCRLRAMP1
SCHEMBL3310446 0.89 CALCRL (0.77) CALCRLRAMP1
SCHEMBL3312152 0.88 CALCRL (0.70) CALCRLRAMP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100113411-A1 Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2010-05-06 US disclosed
EP-1558600-B1 SELECTED CGRP ANTAGONISTS, METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENT BOEHRINGER INGELHEIM PHARMA (DE) 2008-05-07 EP disclosed
CN-1708493-A Selected CGRP antagonists, method for production and use thereof as medicament BOEHRINGER INGELHEIM PHARMA (DE) 2005-12-14 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113411-A1 Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions CALCRL, CALCR, CALCA CALCRL 1/4885RAMP1 84/4885CALCA 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.